1
|
Li H, Hua D, Qu Q, Cao H, Feng Z, Liu N, Huang J, Zhang L. Oral Immunization with Recombinant Saccharomyces cerevisiae Expressing Viral Capsid Protein 2 of Infectious Bursal Disease Virus Induces Unique Specific Antibodies and Protective Immunity. Vaccines (Basel) 2023; 11:1849. [PMID: 38140252 PMCID: PMC10747824 DOI: 10.3390/vaccines11121849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/09/2023] [Accepted: 12/13/2023] [Indexed: 12/24/2023] Open
Abstract
Infectious bursal disease (IBD), as a highly infectious immunosuppressive disease, causes severe economic losses in the poultry industry worldwide. Saccharomyces cerevisiae is an appealing vehicle used in oral vaccine formulations to safely and effectively deliver heterologous antigens. It can elicit systemic and mucosal responses. This study aims to explore the potential as oral an vaccine for S. cerevisiae expressing the capsid protein VP2 of IBDV. We constructed the recombinant S. cerevisiae, demonstrated that VP2 was displayed on the cell surface and had high immunoreactivity. By using the live ST1814G/Aga2-VP2 strain to immunize the mice, the results showed that recombinant S. cerevisiae significantly increased specific IgG and sIgA antibody titers, indicating the potential efficacy of vaccine-induced protection. These results suggested that the VP2 protein-expressing recombinant S. cerevisiae strain was a promising candidate oral subunit vaccine to prevent IBDV infection.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jinhai Huang
- School of Life Sciences, Tianjin University, Tianjin 300072, China; (H.L.); (D.H.); (Q.Q.); (H.C.); (Z.F.); (N.L.)
| | - Lei Zhang
- School of Life Sciences, Tianjin University, Tianjin 300072, China; (H.L.); (D.H.); (Q.Q.); (H.C.); (Z.F.); (N.L.)
| |
Collapse
|
2
|
Effect of Catechin on Yolk Immunoglobulin Structure and Properties: A Polyphenol-Protein Interaction Approach. Foods 2023; 12:foods12030462. [PMID: 36765991 PMCID: PMC9914673 DOI: 10.3390/foods12030462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/13/2023] [Accepted: 01/15/2023] [Indexed: 01/21/2023] Open
Abstract
The preparation of the interaction between polyphenols and protein is of great significance for increasing added value and promoting the application of egg yolk immunoglobulin (IgY). This study systematically investigated the effect of catechin on yolk immunoglobulin structural characteristics and functional properties. The binding conditions, force types, molecular conformation, and residual microenvironment of the interaction between catechin and IgY were analyzed by molecular docking technology, UV-vis absorption and fluorescence spectroscopy studies. The results showed that the main binding forces in the complex were hydrogen bonding and van der Waals forces. After the interaction, fluorescence quenching occurred and the maximum emission wavelength was redshifted. The results showed that the microenvironment around IgY increased polarity, increased hydrophilicity and decreased hydrophobicity, and the structure of the peptide chain changed. The bacteriostatic thermal stability of the compound against Escherichia coli and Staphylococcus aureus was lower than that of catechin IgY. The bacteriostatic acid and base stability were higher than that of catechin and IgY. The antioxidant activity was catechin, complex, and IgY, in descending order. The antioxidant activity of catechin and complex was significantly higher than that of IgY. At the same concentration, the apparent viscosity of the three samples was complex, IgY and catechin, in descending order. G' was greater than G" indicating that elastic properties dominate in G". The G' and G" values of the complex were higher than those of the other groups. Rheological results indicated that the complex may have high physical stability. This study provides theoretical support for broadening the application field of IgY and suggest its properties change in the machining process. It also provides new ideas for the development of functional foods from poultry eggs.
Collapse
|
3
|
Bortolami A, Donini M, Marusic C, Lico C, Drissi Touzani C, Gobbo F, Mazzacan E, Fortin A, Panzarin VM, Bonfante F, Baschieri S, Terregino C. Development of a Novel Assay Based on Plant-Produced Infectious Bursal Disease Virus VP3 for the Differentiation of Infected From Vaccinated Animals. FRONTIERS IN PLANT SCIENCE 2021; 12:786871. [PMID: 34950172 PMCID: PMC8689005 DOI: 10.3389/fpls.2021.786871] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 11/02/2021] [Indexed: 05/28/2023]
Abstract
Infectious bursal disease virus is the causative agent of Gumboro disease, a severe infection that affects young chickens and is associated with lymphoid depletion in the bursa of Fabricius. Traditional containment strategies are based either on inactivated or live-attenuated vaccines. These approaches have several limitations such as residual virulence or low efficacy in the presence of maternally derived antibodies (MDA) but, most importantly, the impossibility to detect the occurrence of natural infections in vaccinated flocks. Therefore, the development of novel vaccination strategies allowing the differentiation of infected from vaccinated animals (DIVA) is a priority. Recently, commercial vectored and experimental subunit vaccines based on VP2 have been proved effective in protecting from clinical disease and posed the basis for the development of novel DIVA strategies. In this study, an engineered version of the VP3 protein of IBDV (His-VP3) was produced in plants, successfully purified from Nicotiana benthamiana leaves, and used to develop an enzyme-linked immunosorbent assay (ELISA) for the detection of anti-VP3 antibodies. The His-VP3 ELISA was validated with a panel of 180 reference sera and demonstrated to have 100% sensitivity (95% CI: 94.7-100.0) and 94.17% specificity (95% CI: 88.4-97.6). To evaluate the application of His-VP3 ELISA as a DIVA test, the novel assay was used to monitor, in combination with a commercial kit, detecting anti-VP2 antibodies, the immune response of chickens previously immunized with an inactivated IBDV vaccine, a recombinant Turkey herpes virus carrying the VP2 of IBDV (HVT-ND-IBD) or with plant-produced VP2 particles. The combined tests correctly identified the immune status of the vaccinated specific pathogen free white-leghorn chickens. Moreover, the His-VP3 ELISA correctly detected MDA against VP3 in commercial broiler chicks and showed that antibody titers fade with time, consistent with the natural decrease of maternally derived immunity. Finally, the novel assay, in combination with a VP2-specific ELISA, demonstrated its potential application as a DIVA test in chickens inoculated with VP2-based vaccines, being able to detect the seroconversion after challenge with a very virulent IBDV strain.
Collapse
Affiliation(s)
- Alessio Bortolami
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Marcello Donini
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Carla Marusic
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Chiara Lico
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Charifa Drissi Touzani
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomic and Veterinary Institute Hassan II, Rabat, Morocco
| | - Federica Gobbo
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Elisa Mazzacan
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Andrea Fortin
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Valentina Maria Panzarin
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Francesco Bonfante
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| | - Selene Baschieri
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Calogero Terregino
- Department of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, Italy
| |
Collapse
|
4
|
Uribe-Diaz S, Nazeer N, Jaime J, Vargas-Bermúdez DS, Yitbarek A, Ahmed M, Rodríguez-Lecompte JC. Folic acid enhances proinflammatory and antiviral molecular pathways in chicken B-lymphocytes infected with a mild infectious bursal disease virus. Br Poult Sci 2021; 63:1-13. [PMID: 34287101 DOI: 10.1080/00071668.2021.1958298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
1. This study evaluated the effect of folic acid (FA) supplementation on the proinflammatory and antiviral molecular pathways of B-lymphocytes infected with a modified live IBDV (ST-12) mild vaccine strain during a timed post-infection analysis.2. A chicken B-lymphocytes (DT-40) cell line was cultured in triplicate at a concentration of 5 × 105 cells per well in 24-well plates; and was divided into three groups: 1: No virus, FA; 2: Virus, no FA; 3: Virus + FA at a concentration of 3.96 mM. The experiment was repeated three times.3. Cells in groups 2 and 3 were infected with a modified live IBDV (ST-12) mild vaccine strain at one multiplicity of infection (MOI: 1). After 1 hour of virus adsorption, samples were collected at 0, 3, 6, 12, 24 and 36 hours post-infection (hpi).4. The modified live IBDV (ST-12) mild vaccine strain triggered a B-lymphocyte specific immune response associated with the upregulation of genes involved in virus recognition (Igß), virus sensing (TLR-2, TLR-3, TLR-4 and MDA5), signal transduction and regulation (TRIF, MyD88 and IRF7), and the antiviral effector molecules (IFN-α, OAS, PKR, and viperin).5. FA supplementation modulated IBDV replication and regulated the proinflammatory and antiviral downstream molecular pathways.6. In conclusion, the low virulent pathotype serotype I modified live IBDV (ST-12) mild vaccine strain was able to trigger and mount an immune response in chicken B-lymphocytes without affecting B-cell viability. FA supplementation modulated B lymphocytes response and improved their innate immune proinflammatory and antiviral response molecular pathways.
Collapse
Affiliation(s)
- S Uribe-Diaz
- Department of Pathology and Microbiology, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Canada.,Department of Chemistry, University of Prince Edward Island, Charlottetown, Canada
| | - N Nazeer
- Department of Chemistry, University of Prince Edward Island, Charlottetown, Canada
| | - J Jaime
- Bogotá. Faculty of Veterinary Medicine and Zootechnic. Animal Health Department; Infectiology and Immunology Research Centre (CI3V), National University of Colombia, Bogotá, Colombia
| | - D S Vargas-Bermúdez
- Bogotá. Faculty of Veterinary Medicine and Zootechnic. Animal Health Department; Infectiology and Immunology Research Centre (CI3V), National University of Colombia, Bogotá, Colombia
| | - A Yitbarek
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Canada
| | - M Ahmed
- Department of Chemistry, University of Prince Edward Island, Charlottetown, Canada
| | - J C Rodríguez-Lecompte
- Department of Pathology and Microbiology, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Canada
| |
Collapse
|
5
|
Marusic C, Drissi Touzani C, Bortolami A, Donini M, Zanardello C, Lico C, Rage E, Fellahi S, El Houadfi M, Terregino C, Baschieri S. The expression in plants of an engineered VP2 protein of Infectious Bursal Disease Virus induces formation of structurally heterogeneous particles that protect from a very virulent viral strain. PLoS One 2021; 16:e0247134. [PMID: 33592038 PMCID: PMC7886152 DOI: 10.1371/journal.pone.0247134] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Accepted: 02/01/2021] [Indexed: 11/18/2022] Open
Abstract
Infectious Bursal Disease Virus (IBDV), the etiological agent of Gumboro disease, causes mortality and immunosuppression in chickens and major losses to poultry industry worldwide. The IBDV major capsid protein VP2 is considered the best candidate for the production of novel subunit vaccines. This structural protein contains the major conformational epitopes responsible for the induction of IBDV neutralizing antibodies in chickens and has been demonstrated able to form supramolecular structures in yeast and insect cells. The aim of this study was to express an engineered version of the VP2 protein (His-pVP2) to verify its ability to self-assemble into virus-like particles in plants. The recombinant VP2 was transiently expressed by agroinfiltration in Nicotiana benthamiana and transmission electron microscopy of sucrose density gradient fractions revealed the presence of a mixed population of differently shaped particles ranging from spherical capsids, with a diameter between ~25 and ~70 nm, to tubular structures, with variable length (from 100 to 400 nm). The recombinant VP2-based particles when used for the intramuscular immunization of specific-pathogen-free chicks resulted able to induce the production of anti-IBDV specific antibodies at titers comparable to those induced by a commercial vaccine. Moreover, all the immunized birds survived to the challenge with a Moroccan very virulent IBDV strain with no major histomorphological alterations of the Bursa of Fabricius, similarly to what obtained with the commercial inactivated vaccine.
Collapse
Affiliation(s)
- Carla Marusic
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Charifa Drissi Touzani
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Alessio Bortolami
- Specialized Virology and Experimental Research Department Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Marcello Donini
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Claudia Zanardello
- Diagnostic Services, Histopathology, Parasitology Department, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Chiara Lico
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Emile Rage
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Siham Fellahi
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Mohammed El Houadfi
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Calogero Terregino
- Specialized Virology and Experimental Research Department Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Selene Baschieri
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| |
Collapse
|
6
|
Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus. Vaccines (Basel) 2021; 9:vaccines9020142. [PMID: 33579020 PMCID: PMC7916800 DOI: 10.3390/vaccines9020142] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 01/26/2021] [Accepted: 02/05/2021] [Indexed: 12/25/2022] Open
Abstract
Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.
Collapse
|
7
|
Li G, Kuang H, Guo H, Cai L, Chu D, Wang X, Hu J, Rong J. Development of a recombinant VP2 vaccine for the prevention of novel variant strains of infectious bursal disease virus. Avian Pathol 2020; 49:557-571. [PMID: 32658552 DOI: 10.1080/03079457.2020.1791314] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Since 2017, novel variant strains of infectious bursal disease virus (nvIBDV) have been detected in China, while the current vaccines on the market against very virulent IBDV have limited protection against this subtype virus. In this context, a strain of the virus has been isolated, and sequencing alignment and bird regression experiments showed that the virus was IBDV, belonging to the nvIBDV subtype (and named IBDV FJ-1812). Furthermore, the Escherichia coli expression system was used to successfully express soluble nvIBDV rVP2, which is specifically recognized by an anti-IBDV standard serum and anti-nvIBDV positive serum, and could be assembled into 14 - 17 nm virus-like particles. Based on the purified nvIBDV rVP2, we developed an IBDV FJ-1812 VP2 VLP vaccine at a laboratory scale to evaluate protection by this vaccine; in addition, we also prepared an IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV and evaluated its cross-protection against nvIBDV. Results of bird experiments showed that the nvIBDV rVP2 vaccine could induce high titres of specific antibodies, completely protect the bursa of Fabricius from viral infection, and provide 100% immune protection to SPF and Ross 308 broiler chickens. Furthermore, the IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV could provide 60% protection for SPF chickens and 80% protection for Ross 308 broiler chickens. This report provides important technical supports for the prevention and control of nvIBDV in the future.
Collapse
Affiliation(s)
- Guopan Li
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Hongyan Kuang
- The First Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China
| | - Huaxiong Guo
- Department of Pathology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China
| | - Lianshen Cai
- State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| | - Dianfeng Chu
- State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| | - Xi Wang
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Jixiong Hu
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Jun Rong
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China.,State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| |
Collapse
|
8
|
Current state-of-the-art in the use of plants for the production of recombinant vaccines against infectious bursal disease virus. Appl Microbiol Biotechnol 2020; 104:2287-2296. [PMID: 31980920 DOI: 10.1007/s00253-020-10397-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 01/14/2020] [Accepted: 01/19/2020] [Indexed: 12/11/2022]
Abstract
Infectious bursal disease is a widely spread threatening contagious viral infection of chickens that induces major damages to the Bursa of Fabricius and leads to severe immunosuppression in young birds causing significant economic losses for poultry farming. The etiological agent is the infectious bursal disease virus (IBDV), a non-enveloped virus belonging the family of Birnaviridae. At present, the treatment against the spread of this virus is represented by vaccination schedules mainly based on inactivated or live-attenuated viruses. However, these conventional vaccines present several drawbacks such as insufficient protection against very virulent strains and the impossibility to differentiate vaccinated animals from infected ones. To overcome these limitations, in the last years, several studies have explored the potentiality of recombinant subunit vaccines to provide an effective protection against IBDV infection. In this review, we will give an overview of these novel types of vaccines with special emphasis on current state-of-the-art in the use of plants as "biofactories" (plant molecular farming). In fact, plants have been thoroughly and successfully characterized as heterologous expression systems for the production of recombinant proteins for different applications showing several advantages compared with traditional expression systems (Escherichia coli, yeasts and insect cells) such as absence of animal pathogens in the production process, improved product quality and safety, reduction of manufacturing costs, and simplified scale-up.
Collapse
|